Jan G. M. Klijn, Els M. J. J. Berns, and John A. FoekensPanel Discussion 1: Advanced Breast CancerManfred Kaufmann and Henning T. Mouridsen Early Breast CancerEarly Breast Cancer: Tamoxifen OverviewCarsten RoseAromatase Inhibitors and Early Breast Cancer Paul E. GossSERMs: Overview in Early Breast CancerIan E. SmithSurrogate and Intermediate Markers in Early Breast CancerMitch DowsettPanel Discussion 2: Early Breast CancerHans-Jorg Senn and William R. MillerNeoadjuvant TherapyNeoadjuvant Endocrine Therapy for Breast Cancer: A Medical Oncologist's PerspectiveMatthew J. EllisNeoadjuvant Therapy: Surgical PerspectivesJ. Michael DixonPathology of Breast Cancer Following Neoadjuvant Endocrine TherapyHironobu Sasano, Takashi Suzuki, and Takuya MoriyaNeoadjuvant Therapy: Prediction of ResponseWilliam R. Miller, T. J. Anderson, S. Iqbal, and J. Michael DixonMechanisms of Resistance to Endocrine TherapyNancy E. HynesPanel Discussion 3: Neoadjuvant TherapyJames N. Ingle and Ian E. SmithChemopreventionEpidemiological Basis of Hormonal Chemoprevention of Breast CancerMalcolm C. Pike, John R. Daniels, and Darcy V. SpicerBreast Carcinogenesis and Its Prevention by Inhibition of Estrogen GenotoxicityJoachim G. LiehrUse of Selective Antiestrogens for the Chemoprevention of Breast CancerTrevor J. PowlesAromatase Inhibitors and Chemoprevention of Breast CancerPaul E. GossPanel Discussion 4: ChemopreventionChristopher C. Benz and Anthony HowellConclusionPanel Discussion 5: Final Discussion and Wrap-UpJames N. Ingle and Ajay BhatnagarIndex This reference evaluates and describes the latest strategies for hormone suppression and blockade in the management of early and advanced stage breast cancer and explores the effects of tamoxifen, selective estrogen receptor modulators (SERMs), aromatase inhibitors, and their combination on both breast cancers and normal tissues.Endocrine Therapy in Breast Cancer details modern techniques for molecular profiling, monitoring, and targeting offers methods to identify high-risk groups evaluates molecular biomarkers in breast cancer assessment examines the potential toxicity of estrogen receptor (ER)-directed endocrine therapy investigates the development of endocrine resistance discusses neoadjuvant and preoperative approaches in patient care reviews mechanisms that lead to estrogen-independent phenotypesSurveying the medical, surgical, and pathological aspects of endocrine therapy, as well as future research opportunities, Endocrine Therapy in Breast Cancer is a concise and in-depth manual for medical, surgical, and radiation oncologists; endocrinologists; gynecologists; obstetricians; pharmacologists; family physicians; reproductive biologists; epidemiologists; and medical school students.

Rezensionen ( 0 )
Noch keine Rezensionen vorhanden.
Sie können die Erörterung eröffnen.
Zitate (0)
Sie können als Erste ein Zitat veröffentlichen.